초록 ▼

세계최초 최고 수준의 연구성과
- 조절 B 세포에 의한 질환 특이적 면역활성세포 억제기전 규명
- 새로운 타입의 조절 B 세포 (CD40hiCD5+ activated Breg) 및 선천성 면역조절 세포 (IL-10+ILCs (ILC10)) 세포 발굴
- 세계 최초 신생물질환 유래 신규 면역조절인자를 이용한 신생물질환 치료법 개발
- 면역질환 치료용 표적화 나노입자를 이용한 면역질환 치료 기술 확립
- 감염면역질환극복을 위한 항균 및 독소제거용 신개념 치료후보 물질 발굴
1. 국제 학술 논문(SCI):

세계최초 최고 수준의 연구성과
- 조절 B 세포에 의한 질환 특이적 면역활성세포 억제기전 규명
- 새로운 타입의 조절 B 세포 (CD40hiCD5+ activated Breg) 및 선천성 면역조절 세포 (IL-10+ILCs (ILC10)) 세포 발굴
- 세계 최초 신생물질환 유래 신규 면역조절인자를 이용한 신생물질환 치료법 개발
- 면역질환 치료용 표적화 나노입자를 이용한 면역질환 치료 기술 확립
- 감염면역질환극복을 위한 항균 및 독소제거용 신개념 치료후보 물질 발굴
1. 국제 학술 논문(SCI): 16 편
2. 국내 특허 출원: 5 건
3. 국제 특허 출원(PCT): 2 건
4. 국내 특허 등록: 1 건
5. 보도자료: 1 건(최완수 교수 및 김혁순 교수: 알레르기 아토피 등 임상적용 연구 응용)
6. 비고: 학술대회 개최 (3회), 학술회의 참석(26회), 인력양성 (석사: 7명, 박사: 1명)

(출처 : 보고서 요약서 3p)

Abstract ▼

Purpose
- Investigation of regulatory mechanism to immune regulatory cells through immune tolerance control
- Development of adoptive immune cell transfer and nanomaterial-based bioactive material delivery system for the treatment of immune diseases
- Promotion of global competitive Basic R

Purpose
- Investigation of regulatory mechanism to immune regulatory cells through immune tolerance control
- Development of adoptive immune cell transfer and nanomaterial-based bioactive material delivery system for the treatment of immune diseases
- Promotion of global competitive Basic Research Laboratory related to local hospitals, institutes, and industries

Contents
1st year: Analysis of distribution and characterization for immune cell in animal models for immune diseases
- Establishment of animal model for immune diseases: autoimmune diseases (rheumarthritis arthritis, colitis, myelencephalitis, and contact hypersensitiveity), infection immune diseases (endotoxin, bacteria, acinetobacter baumannii, and sepsis), and neoplasm diseases (TC-1, CT26 tumor model).
- Analysis of effector cells for autoimmune diseases, infection immune diseases, and neoplasm diseases and their mechanism study.
- Evaluation of physicochemical properties of biopolymer to prepare nanoparticle for immune diseases

2nd year: Investigation for advanced mechanism of immune regulatory cells
- Microarray analysis of immune regulatory cells and stage differentiated immune cells for analysis of target validation.
- Analysis of LC-MS to deduct protein candidate through alteration of immune cell in immune diseases.
- Establishment of immune regulatory factors by Omics analysis.
- Analysis of functional mechanism for advanced regulatory factor in animal model for immune diseases.
- Evaluation of physicochemical properties such as size, surface charge, and drug loading and of intracellular delivery efficiency of nanoparticles.

3rd year: Development of smart nanoparticle system based on advanced immune regulatory factor
- Analysis for interaction between effection cells and regulatory immune cells through controlled immune regulatory factors.
- Analysis of therapeutic efficacy for immune diseases through controlled immune regulatory factors.
- Establishment of smart nanoparticle system using animal models for immune diseases.

4th year: Analysis of therapeutic efficacy in animal models for immune diseases
- Evaluation of therapeutic efficacy for delivery system in animal models for immune diseases
- Analysis for immune tolerance of activated immune cells by virtue of nanoparticle in animal models
- Evaluation of possibility for adoptive immunotherapy

5th year: Optimization of controlled immune diseases based on immune regulatory cells
- Optimization of therapeutic methods for immune disease
- Investigation for interaction of regulatory B cell, tolDC, and MDSC from PBMC of immune diseases patient
- Optimization of effective delivery system for bioactive substance

Developement results
Research Performance
- Evaluation of inhibition mechanism for immune diseases specific-immune cells caused by regulatory B cell.
- Evaluation of advanced regulatory B cell (CD40hiCD5+ activated Breg) and innate immune cell (IL-10+ILCs (ILC10)).
- Development of the world’s therapeutics by neoplasm diseases-derived new immune regulatory factor.
- Establishment of immune diseases therapeutics using targeted nanoparticles.
- New finding of advanced candidates for antibacterial treatment and removal of toxin.
1. International Journal (SCI): 16
2. Internal Pending Patent: 5
3. International Pending Patent (PCT): 2
4. Internal Patent Registration: 1
5. Media Report: 1 (Prof. WS Choi and HS Kim: Application of the Breg treatment for atopic dermatitis)
6. Remark: Symposium (3), Conference Attendance (26), and Professional Manpower Training (Master Course: 7, Doctoral Course: 1)

Expected Contribution
1. Establishment of new paradigm shift for cell-mediated controlled immune system
2. Revitalization of the expert training for controlled immune system based on immune regulatory cells
3. Establishment of laboratory of integrated immunoregulation combined with local hospital and pharmaceutical company to develop a medicine associated with immune diseasesDevelopment of novel therapeutic medicine for immune diseases to overcome limitation of current therapeutic modalities

(출처 : SUMMARY 5p)

목차 Contents

• 표지 ... 1
• 제 출 문 ... 2
• 보고서 요약서 ... 3
• 요 약 문 ... 4
• SUMMARY ... 5
• 목차 ... 6
• 1. 연구개발 목표 및 내용 ... 7
• 가. 최종 목표 ... 7
• 나. 단계목표 ... 7
• 다. 당초 목표의 수정·보완(중요 연구변경) 사유 ... 8
• 라. 1단계 연차별 연구목표 및 내용 ... 8
• 2. 연구 추진전략 및 방법 ... 8
• 가. 공동연구 추진전략 ... 8
• 나. 연구방법 ... 9
• 다. 연구수행체계 ... 11
• 3. 주요 연구개발 결과 ... 15
• 가. 목표달성도 ... 15
• 나. 대표적 연구업적 ... 63
• 다. 기타 연구성과 ... 64
• 4. 연구수행에 따른 문제점 및 개선방향 ... 66
• 5. 연구개발성과 현황 ... 66
• 6. 국가과학기술종합정보시스템에 등록한 연구시설․장비 현황 ... 74
• 7. 기타사항 ... 74
• 끝페이지 ... 75